WO2011024172A3 - Liposomal compositions and uses of same - Google Patents

Liposomal compositions and uses of same Download PDF

Info

Publication number
WO2011024172A3
WO2011024172A3 PCT/IL2010/000703 IL2010000703W WO2011024172A3 WO 2011024172 A3 WO2011024172 A3 WO 2011024172A3 IL 2010000703 W IL2010000703 W IL 2010000703W WO 2011024172 A3 WO2011024172 A3 WO 2011024172A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
liposomal compositions
liposomes
compositions
encapsulate
Prior art date
Application number
PCT/IL2010/000703
Other languages
French (fr)
Other versions
WO2011024172A2 (en
Inventor
Marcelle Machluf
Tomer Bronshtein
Original Assignee
Technion Research & Development Foundation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research & Development Foundation Ltd. filed Critical Technion Research & Development Foundation Ltd.
Priority to EP10761069.3A priority Critical patent/EP2470164B1/en
Priority to CN201080048954XA priority patent/CN102596179A/en
Priority to US13/392,575 priority patent/US9642817B2/en
Publication of WO2011024172A2 publication Critical patent/WO2011024172A2/en
Publication of WO2011024172A3 publication Critical patent/WO2011024172A3/en
Priority to US15/498,526 priority patent/US10292933B2/en
Priority to US16/372,449 priority patent/US11065203B2/en
Priority to US17/316,749 priority patent/US20210267892A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5176Compounds of unknown constitution, e.g. material from plants or animals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

Compositions comprising liposomes composed of whole cell membrane fraction are provided. The liposomes may be attached to, or encapsulate a pharmaceutical agent. Also provided are methods of generating and using these liposomes.
PCT/IL2010/000703 2009-08-27 2010-08-26 Liposomal compositions and uses of same WO2011024172A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP10761069.3A EP2470164B1 (en) 2009-08-27 2010-08-26 Liposomal compositions and uses of same
CN201080048954XA CN102596179A (en) 2009-08-27 2010-08-26 Liposomal compositions and uses of same
US13/392,575 US9642817B2 (en) 2009-08-27 2010-08-26 Liposomal compositions and uses of same
US15/498,526 US10292933B2 (en) 2009-08-27 2017-04-27 Liposomal compositions and uses of same
US16/372,449 US11065203B2 (en) 2009-08-27 2019-04-02 Liposomal compositions and uses of same
US17/316,749 US20210267892A1 (en) 2009-08-27 2021-05-11 Liposomal compositions and uses of same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23730609P 2009-08-27 2009-08-27
US61/237,306 2009-08-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/392,575 A-371-Of-International US9642817B2 (en) 2009-08-27 2010-08-26 Liposomal compositions and uses of same
US15/498,526 Continuation US10292933B2 (en) 2009-08-27 2017-04-27 Liposomal compositions and uses of same

Publications (2)

Publication Number Publication Date
WO2011024172A2 WO2011024172A2 (en) 2011-03-03
WO2011024172A3 true WO2011024172A3 (en) 2011-05-26

Family

ID=43618635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2010/000703 WO2011024172A2 (en) 2009-08-27 2010-08-26 Liposomal compositions and uses of same

Country Status (4)

Country Link
US (4) US9642817B2 (en)
EP (1) EP2470164B1 (en)
CN (2) CN102596179A (en)
WO (1) WO2011024172A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2020221E (en) * 2007-06-19 2012-05-30 Neubourg Skin Care Gmbh & Co Kg Dms (derma membrane structure) in foaming creams
CN102596179A (en) * 2009-08-27 2012-07-18 工业研究与发展基金会有限公司 Liposomal compositions and uses of same
WO2011116219A1 (en) * 2010-03-17 2011-09-22 Board Of Regent Of The University Of Texas System Theranostic delivery systems with modified surfaces
IT1401457B1 (en) * 2010-06-11 2013-07-26 Fond I R C C S Istituto Neurologico Carlo Besta CARRIER OF CELL TYPE FOR THE SIGHTED TRANSPORT OF AT LEAST ONE MOLECULE AND / OR AT LEAST A MOLECULAR COMPOUND AT LEAST ONE TARGET CELL IN A HUMAN OR NON-HUMAN MAMMALY
US10888625B2 (en) * 2012-10-30 2021-01-12 Particle Sciences, Inc. Drug delivery particle formulations with targeting moieties
US9796960B2 (en) * 2014-01-13 2017-10-24 Mingjie Zhang Method for preparing and using cell ghost with active factors as synergist of lymphocyte in vitro culture
WO2017027771A1 (en) * 2015-08-13 2017-02-16 Dyax Corp. Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
JP6289705B1 (en) * 2017-03-31 2018-03-07 Jsr株式会社 Method for producing probe binding carrier, probe binding carrier and method for detecting or separating target substance
CA3062426A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
KR20200044806A (en) * 2017-07-28 2020-04-29 내셔널 유니버시티 오브 싱가포르 Biomolecule complex containing modified ghost cells
AU2019222560A1 (en) 2018-02-17 2020-08-27 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
WO2020023436A1 (en) * 2018-07-23 2020-01-30 Campbell Robert B Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy
CN110215514B (en) * 2019-04-22 2023-09-05 上海瑞可新生物科技有限公司 Genetically engineered cell membrane nano vesicle and preparation and application thereof
CN112716915A (en) * 2021-02-03 2021-04-30 中国药科大学 Bionic nano-carrier and application thereof in preparing medicament for treating brain glioma
CN112957459B (en) * 2021-02-07 2022-10-28 天津大学 Tumor combined immune nano-particles based on influenza virus, preparation method thereof and application thereof in preparing nano-vaccine
CA3222298A1 (en) 2021-06-13 2022-12-22 Osnat BOHANA-KASHTAN Compositions comprising spherical particles and uses of same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120797A (en) * 1996-10-15 2000-09-19 The Liposome Company, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE3751873T2 (en) 1986-04-09 1997-02-13 Genzyme Corp Genetically transformed animals that secrete a desired protein in milk
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
ES2537516T3 (en) * 2008-02-22 2015-06-09 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles
CN102596179A (en) 2009-08-27 2012-07-18 工业研究与发展基金会有限公司 Liposomal compositions and uses of same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120797A (en) * 1996-10-15 2000-09-19 The Liposome Company, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IMMORDINO MARIA LAURA ET AL: "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", INTERNATIONAL JOURNAL OF NANOMEDICINE, DOVE MEDICAL PRESS LTD, AUCKLAND, NZ, vol. 1, no. 3, 1 January 2006 (2006-01-01), pages 297 - 315, XP009145524, ISSN: 1176-9114 *
WESTERMAN LARRY E ET AL: "Liposomes composed of reconstituted membranes for induction of tumor-specific immunity", METHODS IN ENZYMOLOGY; [METHODS IN ENZYMOLOGY], ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 373, 1 January 2003 (2003-01-01), pages 118 - 127, XP009145463, ISSN: 0076-6879 *

Also Published As

Publication number Publication date
EP2470164B1 (en) 2017-05-31
US9642817B2 (en) 2017-05-09
EP2470164A2 (en) 2012-07-04
US20210267892A1 (en) 2021-09-02
US20120164214A1 (en) 2012-06-28
WO2011024172A2 (en) 2011-03-03
CN102596179A (en) 2012-07-18
US11065203B2 (en) 2021-07-20
US20190224125A1 (en) 2019-07-25
US20170224618A1 (en) 2017-08-10
US10292933B2 (en) 2019-05-21
CN106619515A (en) 2017-05-10

Similar Documents

Publication Publication Date Title
WO2011024172A3 (en) Liposomal compositions and uses of same
WO2011106109A3 (en) Nanotape and nanocarpet materials
WO2010111409A3 (en) Pluripotent stem cells
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2011107462A3 (en) Sun protection compositions
WO2012024452A3 (en) Modified relaxin polypeptides and their uses
EP2659956A4 (en) Composite semipermeable membrane
WO2009149956A3 (en) Fusion protein and use thereof
EP2165694B8 (en) Vesicle useful for external preparation for skin, and external preparation for skin comprising the vesicle
EP2660917A4 (en) Unit cell of metal-supported solid oxide fuel cell, preparation method thereof, and solid oxide fuel cell stack using the unit cell
EP2190307A4 (en) Preparation method of vegetable extract ferment solution and vegetable extract ferment solution prepared by the same
EP2361303B8 (en) An isolated multipotent mesenchymal stem cell from human adult glomeruli (hgl-msc), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
WO2010111659A8 (en) Tumor-initiating cells and methods for using same
EP2484336A4 (en) Pigment for cosmetic preparations, method for producing same, and cosmetic preparation containing the pigment for cosmetic preparations
ZA201209738B (en) Levoisovalerylspiramycin i,ii,iii and preparations,preparation methods and uses thereof
EP2262039B8 (en) Battery separator and battery using the same
WO2012002730A3 (en) Skin-whitening and skin-moisturizing composition containing bee venom extracts
EP2404591A4 (en) Cosmetic preparation, method for producing same, composition for cosmetic preparations, cosmetic preparation containing the composition for cosmetic preparations and method for producing same, and cleanser for industrial use
WO2012024350A3 (en) Anti-cancer adenoviruses
GB0912378D0 (en) Sterols modified by polyethylene glycol, the preparation and the use thereof
WO2012084423A3 (en) Active ingredient combinations of glyceryl glucosides and one or more mild surfactants
ZA201009097B (en) C-ring-substituted pregn-4-ene-21,17-carbolactone,and pharmaceutical preparations comprising the latter
WO2012021678A3 (en) Isolated bacteria, methods for use, and methods for isolation
WO2011029102A3 (en) Cd117+cells and uses thereof
WO2012036414A3 (en) Cosmetic composition comprising a fermented soybean extract fraction as an active ingredient

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080048954.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10761069

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13392575

Country of ref document: US

Ref document number: 484/MUMNP/2012

Country of ref document: IN

REEP Request for entry into the european phase

Ref document number: 2010761069

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010761069

Country of ref document: EP